Nuvectis Pharma Files 8-K for Material Agreement
Ticker: NVCT · Form: 8-K · Filed: Feb 6, 2025 · CIK: 1875558
| Field | Detail |
|---|---|
| Company | Nuvectis Pharma, Inc. (NVCT) |
| Form Type | 8-K |
| Filed Date | Feb 6, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001, $5.00, $14.4 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing, corporate-event
Related Tickers: NUVT
TL;DR
Nuvectis Pharma (NUVT) filed an 8-K on Feb 5th for a material definitive agreement. Big news pending.
AI Summary
On February 5, 2025, Nuvectis Pharma, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits. Nuvectis Pharma, Inc. is incorporated in Delaware and its principal executive offices are located in Fort Lee, NJ.
Why It Matters
This filing indicates a significant development for Nuvectis Pharma, Inc., potentially involving a new partnership, acquisition, or other material contract that could impact its business operations and future prospects.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce significant opportunities or risks depending on the nature of the agreement, which is not fully detailed in this initial filing.
Key Players & Entities
- Nuvectis Pharma, Inc. (company) — Registrant
- February 5, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Fort Lee, NJ (location) — Principal Executive Offices
FAQ
What is the nature of the material definitive agreement entered into by Nuvectis Pharma, Inc. on February 5, 2025?
The filing states that Nuvectis Pharma, Inc. entered into a material definitive agreement on February 5, 2025, but the specific details of this agreement are not provided in the provided text.
What other events are reported in this 8-K filing?
The filing indicates 'Other Events' are reported, alongside the entry into a material definitive agreement and the filing of financial statements and exhibits.
Where are Nuvectis Pharma, Inc.'s principal executive offices located?
Nuvectis Pharma, Inc.'s principal executive offices are located at 1 Bridge Plaza Suite 275, Fort Lee, NJ 07024.
When was this 8-K report filed?
This 8-K report was filed as of February 6, 2025, with the earliest event reported being February 5, 2025.
What is Nuvectis Pharma, Inc.'s Standard Industrial Classification (SIC) code?
Nuvectis Pharma, Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 867 words · 3 min read · ~3 pages · Grade level 11.2 · Accepted 2025-02-05 21:51:21
Key Financial Figures
- $0.00001 — Shares") of the Company's common stock, $0.00001 par value per share ("Common Stock"), a
- $5.00 — on Stock"), at a price to the public of $5.00 per share, less underwriting discounts
- $14.4 m — fering are expected to be approximately $14.4 million, after deducting underwriting dis
Filing Documents
- tm255441d1_8k.htm (8-K) — 28KB
- tm255441d1_ex1-1.htm (EX-1.1) — 204KB
- tm255441d1_ex5-1.htm (EX-5.1) — 14KB
- tm255441d1_ex99-1.htm (EX-99.1) — 11KB
- tm255441d1_ex99-2.htm (EX-99.2) — 12KB
- tm255441d1_ex5-1img001.jpg (GRAPHIC) — 6KB
- tm255441d1_ex99-1img002.jpg (GRAPHIC) — 15KB
- tm255441d1_ex99-2img001.jpg (GRAPHIC) — 7KB
- 0001104659-25-009813.txt ( ) — 547KB
- nvct-20250205_lab.xml (EX-101.LAB) — 33KB
- nvct-20250205_pre.xml (EX-101.PRE) — 22KB
- nvct-20250205.xsd (EX-101.SCH) — 3KB
- tm255441d1_8k_htm.xml (XML) — 4KB
01. Other
Item 8.01. Other Events. On February 4, 2025, the Company issued a press release announcing the launch of the Offering. On February 5, 2025, the Company issued a press release announcing it had priced the Offering. Copies of the press releases are filed as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference. Item 9.01. Financial Statements and Exhibits. (d) Exhibits The following exhibits are filed as a part of this report: Exhibit Number Description 1.1 Underwriting Agreement dated February 5, 2025, between Nuvectis Pharma, Inc. and Lucid Capital Markets, LLC. 5.1 Opinion of Alston & Bird LLP. 23.1 Consent of Alston & Bird LLP (included in the opinion filed as Exhibit 5.1). 99.1 Launch Press Release, dated February 4, 2025. 99.2 Pricing Press Release, dated February 5, 2025. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Nuvectis Pharma, Inc. (Registrant) Date: February 5, 2025 By: /s/ Ron Bentsur Ron Bentsur Chairman, Chief Executive Officer and President